Approval extended

Novavax now approved for adolescents, TGA announces The Therapeutic Goods Administration (TGA) has announced it has provisionally approved the Biocelect (on behalf of Novavax) COVID-19 vaccine, Nuvaxovid, for use in individuals aged 12-17 years. The decision followed the provisional approval granted on 19 January 2022 for the use of Nuvaxovid in adults. On 9 June

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Research Roundup
Next Pharmacy approval appeal rejected